Aevi Genomic Medicine has completed patient enrolment for Part B of its ASCEND clinical trial.

The Phase II study will evaluate the safety and efficacy of AEVI-001 in pediatric and adolescent patients with attention deficit hyperactivity disorder (ADHD).

The adaptive, six-week, genomically guided trial comprises parts A and B.

Part A of the trial will investigate a mGluR mutation positive genetic subset of paediatric and adolescent patients, while Part B will examine paediatric and adolescent patients with ADHD without metabotropic glutamate receptor (mGluR) mutations.

In August, Aevi completed enrolling patients for Part A, which features subjects who have one of the eight specific gene mutations implicated in glutamatergic signalling and neuronal connectivity.

Part B includes patients who do not have copy number variants (CNVs) in any of the specific gene mutation(s) implicated in glutamatergic signalling and neuronal connectivity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“AEVI-001 is a unique, oral, non-stimulant activator/modulator of mGluRs, with the potential to help many patients.”

The subjects are expected to be randomised in 1:1 ratio into one of two treatment groups, AEVI-001 or placebo.

Topline results from Parts A and B of Aevi’s ASCEND trial are scheduled to be available by January next year.

The company plans to conduct individual and pooled analysis for both parts simultaneously, and will provide data on the design of a planned Phase III programme.

Aevi Genomic Medicine chief scientific officer Garry Neil said: “Attention deficit hyperactivity disorder affects millions of paediatric and adolescent patients and despite a number of drugs on the market today, we believe treatment is suboptimal for many patients.

“AEVI-001 is a unique, oral, non-stimulant activator/modulator of mGluRs, with the potential to help many patients and their families.”

AEVI-001 contains improved pharmacokinetic and metabolic profiles, and crosses the blood brain barrier.

The investigational product is yet to receive approval from the US Food and Drug Administration, or any other regulatory agencies.